Shopping Cart
- Remove All
Your shopping cart is currently empty
Odevixibat (A4250) is an effective, selective and orally active ileal bile acid transporter inhibitor. Odevixibat has the potential for the treatment of primary biliary cirrhosis. Odevixibat reduces cholestatic liver and bile duct injury in mice model.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $31 | In Stock | |
| 5 mg | $123 | In Stock | |
| 10 mg | $198 | In Stock | |
| 25 mg | $372 | In Stock | |
| 50 mg | $619 | In Stock | |
| 100 mg | $987 | In Stock | |
| 200 mg | $1,330 | In Stock |
| Description | Odevixibat (A4250) is an effective, selective and orally active ileal bile acid transporter inhibitor. Odevixibat has the potential for the treatment of primary biliary cirrhosis. Odevixibat reduces cholestatic liver and bile duct injury in mice model. |
| In vivo | Odevixibat obviously decreases bile flow and biliary BA output, which correlates with reduced bsep transcription, while Ntcp and Cyp7a1 are induced. Odevixibat (0.01% (w/w) in chow diet; 4 weeks) improves sclerosing cholangitis and significantly decreases serum alanine aminotransferase, alkaline phosphatase and BAs levels, hepatic expression of pro-inflammatory and pro-fibrogenic genes and bile duct proliferation in Mdr2-/- mice [1]. |
| Synonyms | A4250 |
| Molecular Weight | 740.93 |
| Formula | C37H48N4O8S2 |
| Cas No. | 501692-44-0 |
| Smiles | CCCCC1(CCCC)CN(c2ccccc2)c2cc(SC)c(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)c3ccc(O)cc3)cc2S(=O)(=O)N1 |
| Relative Density. | 1.34 g/cm3 (Predicted) |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 150.0 mg/mL (202.5 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (6.75 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.